{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:42:01Z","timestamp":1790613721103,"version":"4.1.0"},"reference-count":41,"publisher":"Society of Nuclear Medicine","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.2967\/jnumed.121.262562","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T16:10:33Z","timestamp":1636733433000},"page":"1033-1038","source":"Crossref","is-referenced-by-count":38,"title":["Glypican-3\u2013Targeted <sup>227<\/sup>Th <b>\u03b1<\/b>-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma"],"prefix":"10.2967","volume":"63","author":[{"given":"Kevin P.","family":"Labadie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald K.","family":"Hamlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Kenoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara K.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"Utria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Kenerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Sham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine L.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnnie J.","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond S.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Orvig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Wilbur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,11,12]]},"reference":[{"key":"2022070608400720000_63.7.1033.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2022070608400720000_63.7.1033.2","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hep.30161","article-title":"Changing trends in etiology-based and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology."},{"key":"2022070608400720000_63.7.1033.3","doi-asserted-by":"crossref","first-page":"45846","DOI":"10.1038\/srep45846","article-title":"International incidence and mortality trends of liver cancer: a global profile","volume":"7","author":"Wong","year":"2017","journal-title":"Sci Rep."},{"key":"2022070608400720000_63.7.1033.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2022070608400720000_63.7.1033.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"key":"2022070608400720000_63.7.1033.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152"},{"key":"2022070608400720000_63.7.1033.7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4012"},{"key":"2022070608400720000_63.7.1033.8","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Parker","year":"2018","journal-title":"JAMA Oncol."},{"key":"2022070608400720000_63.7.1033.9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.108.058651"},{"key":"2022070608400720000_63.7.1033.10","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2008.05.002"},{"key":"2022070608400720000_63.7.1033.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.186338"},{"key":"2022070608400720000_63.7.1033.12","doi-asserted-by":"crossref","first-page":"86937","DOI":"10.18632\/oncotarget.13520","article-title":"Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas\u2019 sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation","volume":"7","author":"Malamas","year":"2016","journal-title":"Oncotarget."},{"key":"2022070608400720000_63.7.1033.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2016.07.034"},{"key":"2022070608400720000_63.7.1033.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3476"},{"key":"2022070608400720000_63.7.1033.15","doi-asserted-by":"crossref","first-page":"56311","DOI":"10.18632\/oncotarget.16910","article-title":"Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in\u00a0vitro and in\u00a0vivo models of renal cell carcinoma","volume":"8","author":"Hagemann","year":"2017","journal-title":"Oncotarget."},{"key":"2022070608400720000_63.7.1033.16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0251"},{"key":"2022070608400720000_63.7.1033.17","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.223701"},{"key":"2022070608400720000_63.7.1033.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)00908-2"},{"key":"2022070608400720000_63.7.1033.19","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","journal-title":"Am J Pathol."},{"key":"2022070608400720000_63.7.1033.20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.3390\/cancers11091339","article-title":"Glypican 3-targeted therapy in hepatocellular carcinoma","volume":"11","author":"Nishida","year":"2019","journal-title":"Cancers (Basel)."},{"key":"2022070608400720000_63.7.1033.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.145102"},{"key":"2022070608400720000_63.7.1033.22","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.132118"},{"key":"2022070608400720000_63.7.1033.23","doi-asserted-by":"crossref","first-page":"4564707","DOI":"10.1155\/2019\/4564707","article-title":"Yttrium-90-labeled anti-glypican 3 radioimmunotherapy halts tumor growth in an orthotopic xenograft model of hepatocellular carcinoma","volume":"2019","author":"Ludwig","year":"2019","journal-title":"J Oncol."},{"key":"2022070608400720000_63.7.1033.24","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/jlcr.3875","article-title":"Thorium chelators for targeted alpha therapy: rapid chelation of thorium-226","volume":"63","author":"Ferrier","year":"2020","journal-title":"J Labelled Comp Radiopharm."},{"key":"2022070608400720000_63.7.1033.25","doi-asserted-by":"crossref","first-page":"8670","DOI":"10.1021\/ja3024725","article-title":"H4octapa: an acyclic chelator for 111In radiopharmaceuticals","volume":"134","author":"Price","year":"2012","journal-title":"J Am Chem Soc."},{"key":"2022070608400720000_63.7.1033.26","doi-asserted-by":"publisher","DOI":"10.1021\/ja4049493"},{"key":"2022070608400720000_63.7.1033.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(07)26007-0"},{"key":"2022070608400720000_63.7.1033.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2513"},{"key":"2022070608400720000_63.7.1033.29","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1113\/EP088870","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"105","author":"Percie du Sert","year":"2020","journal-title":"Exp Physiol."},{"key":"2022070608400720000_63.7.1033.30","doi-asserted-by":"publisher","DOI":"10.1038\/laban1005-39"},{"key":"2022070608400720000_63.7.1033.31","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/molecules26010004","article-title":"Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma","volume":"26","author":"Bell","year":"2020","journal-title":"Molecules."},{"key":"2022070608400720000_63.7.1033.32","unstructured":"Kelada OJ Gutsche NT Bell M .ImmunoPET as stoichiometric sensor for glypican-3 in models of hepatocellular carcinoma. BioRxiv website. https:\/\/www.biorxiv.org\/content\/10.1101\/2020.01.31.926972v1.full. Published February 2, 2020. Accessed February 23, 2022."},{"key":"2022070608400720000_63.7.1033.33","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41598-021-82172-w","article-title":"Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma","volume":"11","author":"Labadie","year":"2021","journal-title":"Sci Rep."},{"key":"2022070608400720000_63.7.1033.34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001250"},{"key":"2022070608400720000_63.7.1033.35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-467035"},{"key":"2022070608400720000_63.7.1033.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"2022070608400720000_63.7.1033.37","doi-asserted-by":"publisher","DOI":"10.1038\/274365a0"},{"key":"2022070608400720000_63.7.1033.38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1600-0609.1989.tb00271.x","article-title":"Thymus and T cells are not essential for rat leucopoiesis","volume":"43","author":"Benestad","year":"1989","journal-title":"Eur J Haematol."},{"key":"2022070608400720000_63.7.1033.39","first-page":"5055","article-title":"Up-regulation of glypican-3 in human hepatocellular carcinoma","volume":"30","author":"Suzuki","year":"2010","journal-title":"Anticancer Res."},{"key":"2022070608400720000_63.7.1033.40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7536"},{"key":"2022070608400720000_63.7.1033.41","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.174300"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:42:57Z","timestamp":1657122177000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,12]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,6,30]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.2967\/jnumed.121.262562"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262562","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,12]]}}}